mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. (Q38007148)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22553196%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

title

mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22553196%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22553196%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Fabrice André

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22553196%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

author name string

C Villarreal-Garza

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22553196%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

S Verma

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22553196%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

language of work or name

1 reference

2 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22553196%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22553196%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22553196%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22553196%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

page(s)

2526-2535

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22553196%20AND%20SRC:MED&resulttype=core&format=json

Optimizing endocrine therapy for breast cancer

31 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Advances in adjuvant endocrine therapy for postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Endocrine therapy of metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficac

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Letrozole in advanced breast cancer: the PO25 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Mechanisms of Endocrine Resistance in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

"Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Somatic mutation and gain of copy number of PIK3CA in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Proliferation marker Ki-67 in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Targeted therapies in breast cancer: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

The effectiveness of commonly used mouthwashes for the prevention of chemotherapy-induced oral mucositis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075

Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS075